Pinnbrook Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-96,851
Closed -$3.02M 110
2025
Q4
$3.02M Buy
96,851
+93,885
+3,165% +$2.31M 0.42% 70
2025
Q3
$59.9K Buy
+2,966
New +$52.1K 0.01% 139
2025
Q1
Sell
-225,320
Closed -$4.97M 111
2024
Q4
$4.97M Buy
+225,320
New +$4.1M 0.49% 44
2024
Q3
Sell
-470,554
Closed -$7.65M 100
2024
Q2
$7.65M Buy
470,554
+8,854
+2% +$136K 1.61% 22
2024
Q1
$6.51M Buy
+461,700
New +$5.82M 0.55% 62

Other funds holding TEVA

Pinnbrook Capital Management's TEVA Position: Q1 2026 in Review

Pinnbrook Capital Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q1 2026, closing a stake of 96,851 shares — an estimated $3.02M sold.

Pinnbrook Capital Management first reported a position in TEVA in Q1 2024 and held it in 5 quarters. The position peaked at $7.65M in Q2 2024. 653 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Pinnbrook Capital Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q1 2026 after selling out during the quarter.
  • Pinnbrook Capital Management sold 96,851 Teva Pharmaceutical Industries Limited shares in Q1 2026, an estimated $3.02M.
  • Pinnbrook Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q1 2024 and held it in 5 quarters.
  • Pinnbrook Capital Management's Teva Pharmaceutical Industries Limited position peaked at $7.65M in Q2 2024.
  • 653 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2026.

Based on Pinnbrook Capital Management's 13F filing for Q1 2026, filed 14 May 2026.